
    
      Primary Objective:

      To evaluate the efficacy of sorafenib with weekly bortezomib, as measured by objective
      response rate and progression-free survival in patients with relapsed/refractory multiple
      myeloma.

      Secondary Objective:

      To evaluate the feasibility and toxicity of sorafenib with weekly bortezomib in the treatment
      of patients with relapsed/refractory multiple myeloma.
    
  